Ocular Therapeutix (NASDAQ:OCUL) Insider Sanjay Nayak Sells 1,759 Shares

February 26, 2026 by InsiderTrades.com

Key Points

Pravin Dugel sold 20,056 shares on Feb. 23 at $8.28 for $166,063.68 (after selling 124,882 shares on Feb. 12 at $9.04), part of clustered executive sales that could increase supply and pressure sentiment.
OCUL traded down ~3.1% to $9.21 while short interest jumped ~27.8% to ~14.7M shares (~6.9% of float); analysts hold a consensus "Moderate Buy" with an average target of $23.78, and the company recently beat EPS (-$0.29 vs. -$0.33) but missed revenue, which fell 22.4% year‑over‑year.

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) insider Sanjay Nayak sold 1,759 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $8.28, for a total value of $14,564.52. Following the completion of the sale, the insider owned 330,653 shares of the company's stock, valued at approximately $2,737,806.84. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Sanjay Nayak also recently made the following trade(s):

On Thursday, February 12th, Sanjay Nayak sold 10,348 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.04, for a total value of $93,545.92.

Ocular Therapeutix Trading Down 2.9%

Shares of Ocular Therapeutix stock traded down $0.28 during midday trading on Thursday, reaching $9.23. 4,539,561 shares of the company's stock traded hands, compared to its average volume of 6,989,396. The stock has a 50 day moving average of $10.45 and a 200-day moving average of $11.61. Ocular Therapeutix, Inc. has a 12 month low of $5.78 and a 12 month high of $16.44. The company has a market cap of $2.01 billion, a PE ratio of -6.41 and a beta of 0.90. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The business had revenue of $13.25 million for the quarter, compared to the consensus estimate of $16.13 million. During the same period in the previous year, the firm earned ($0.29) EPS. The company's quarterly revenue was down 22.4% compared to the same quarter last year. As a group, equities analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

OCUL has been the topic of several research reports. HC Wainwright lifted their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the company a "buy" rating in a research report on Monday, December 8th. Royal Bank Of Canada restated an "outperform" rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research note on Thursday, February 5th. Wall Street Zen raised Ocular Therapeutix from a "sell" rating to a "hold" rating in a research note on Saturday, February 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. Finally, TD Cowen restated a "buy" rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.78.

Read Our Latest Report on OCUL

Institutional Investors Weigh In On Ocular Therapeutix

Several institutional investors have recently modified their holdings of OCUL. Vanguard Group Inc. lifted its stake in Ocular Therapeutix by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company's stock valued at $140,523,000 after acquiring an additional 2,411,953 shares during the period. Avoro Capital Advisors LLC raised its stake in Ocular Therapeutix by 5.1% during the 4th quarter. Avoro Capital Advisors LLC now owns 10,777,777 shares of the biopharmaceutical company's stock valued at $130,842,000 after buying an additional 527,777 shares during the last quarter. TCG Crossover Management LLC raised its stake in Ocular Therapeutix by 15.0% during the 3rd quarter. TCG Crossover Management LLC now owns 6,117,232 shares of the biopharmaceutical company's stock valued at $71,510,000 after buying an additional 798,084 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Ocular Therapeutix by 15.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,625,050 shares of the biopharmaceutical company's stock valued at $56,148,000 after buying an additional 620,700 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Ocular Therapeutix by 30.5% in the 4th quarter. Geode Capital Management LLC now owns 4,356,547 shares of the biopharmaceutical company's stock worth $52,896,000 after buying an additional 1,018,094 shares during the last quarter. 59.21% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

Positive Sentiment: Director Richard L. Lindstrom made a sizable purchase of 60,229 shares at ~$7.66, increasing his stake ~32% — a strong signal of insider confidence and direct demand support. SEC Filing - Lindstrom Form 4
Positive Sentiment: Ocular will present detailed SOL‑1 data at the Macula Society meeting and host investor events — favorable readouts or management commentary could be a major upside catalyst. SOL‑1 Presentation
Neutral Sentiment: Market positioning: equities analysts remain largely bullish (consensus “Moderate Buy” with a wide target range), so upcoming earnings/updates could swing sentiment either way. MarketBeat Summary
Neutral Sentiment: Smaller insider sale by Nadia Waheed (3,510 shares at ~$7.74) — modest disposition relative to holdings and unlikely alone to alter long‑term conviction. SEC Filing - Waheed Form 4
Negative Sentiment: Clustered executive selling on Feb 23 — several insiders (S. Nayak, J. Heier, P. Kaiser and notably Pravin Dugel selling 20,056 shares) sold at ~ $8.28, increasing available float and weighing on near‑term sentiment. SEC Filing - Dugel Form 4
Negative Sentiment: Short interest rose ~27.8% in February to ~14.7M shares (~6.9% of float), elevating bearish pressure and the potential for heightened volatility around catalysts.
Negative Sentiment: Needham trimmed its price target to $18 (from $20), a downside revision that could temper enthusiasm despite other buy ratings. Needham Price Target Cut

About Ocular Therapeutix

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company's flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.